

BREVET D'INVENTION
CERTIFICAT D'UTILITÉ

REQUÊTE EN DÉLIVRANCE 2/2

REMISE DES PIÈCES	Réervé à l'INPI
DATE	27 FÉV 2001
LIEU	75 INPI PARIS
N° D'ENREGISTREMENT	0102631
NATIONAL ATTRIBUÉ PAR L'INPI	

DB 540 W /260899

Vos références pour ce dossier : <i>(facultatif)</i>		RS Cas 312 - AB/CG
6 MANDATAIRE		
Nom		BOURGOUIN
Prénom		André
Cabinet ou Société		BEAUFOUR IPSEN - S.C.R.A.S. Direction de la Propriété Industrielle
N °de pouvoir permanent et/ou de lien contractuel		En cours d'enregistrement
Adresse	Rue	42 rue du Docteur Blanche
	Code postal et ville	75016 PARIS
N° de téléphone <i>(facultatif)</i>		(33) 01 44 30 43 43
N° de télécopie <i>(facultatif)</i>		(33) 01 44 30 43 80
Adresse électronique <i>(facultatif)</i>		andre.bourgouin@beaufour-ipsen.com
7 INVENTEUR (S)		
Les inventeurs sont les demandeurs		<input type="checkbox"/> Oui <input checked="" type="checkbox"/> Non Dans ce cas fournir une désignation d'inventeur(s) séparée
8 RAPPORT DE RECHERCHE		Uniquement pour une demande de brevet (y compris division et transformation)
Établissement immédiat ou établissement différé		<input checked="" type="checkbox"/> <input type="checkbox"/>
Paiement échelonné de la redevance		Paiement en deux versements, uniquement pour les personnes physiques <input type="checkbox"/> Oui <input checked="" type="checkbox"/> Non
9 RÉDUCTION DU TAUX DES REDEVANCES		Uniquement pour les personnes physiques <input type="checkbox"/> Requise pour la première fois pour cette invention (<i>joindre un avis de non-imposition</i>) <input type="checkbox"/> Requise antérieurement à ce dépôt (<i>joindre une copie de la décision d'admission pour cette invention ou indiquer sa référence</i>):
Si vous avez utilisé l'imprimé «Suite», indiquez le nombre de pages jointes		
10 SIGNATURE DU DEMANDEUR OU DU MANDATAIRE <i>(Nom et qualité du signataire)</i>		VISA DE LA PRÉFECTURE OU DE L'INPI
 A. BOURGOUIN, Mandataire		 C. TRAN



INSTITUT NATIONAL DE

LA PROPRIÉTÉ INDUSTRIELLE

26 bis, rue de Saint Pétersbourg

75800 Paris Cedex 08

Téléphone : 01 53 04 53 04 Télécopie : 01 42 94 86 54

BREVET D'INVENTION

CERTIFICAT D'UTILITÉ

Code de la propriété intellectuelle - Livre VI



N° 11354*01

REQUÊTE EN DÉLIVRANCE 1/2

Cet imprimé est à remplir lisiblement à l'encre noire

DB 540 W /260899

REMISE DES PIÈCES DATE LIEU		Réserve à l'INPI 27 FEV 2001 75 INPI PARIS
N° D'ENREGISTREMENT NATIONAL ATTRIBUÉ PAR L'INPI		0102631
DATE DE DÉPÔT ATTRIBUÉE PAR L'INPI		27 FEV. 2001
Vos références pour ce dossier (facultatif) RS Cas 312 - AB/CG		

**1 NOM ET ADRESSE DU DEMANDEUR OU DU MANDATAIRE
À QUI LA CORRESPONDANCE DOIT ÊTRE ADRESSÉE**

Monsieur André BOURGOUIN
BEAUFOUR IPSEN - S.C.R.A.S.
Direction de la Propriété Industrielle
42 rue du Docteur Blanche
75016 PARIS

Confirmation d'un dépôt par télécopie N° attribué par l'INPI à la télécopie

2 NATURE DE LA DEMANDE	Cochez l'une des 4 cases suivantes		
Demande de brevet	<input checked="" type="checkbox"/>		
Demande de certificat d'utilité	<input type="checkbox"/>		
Demande divisionnaire	<input type="checkbox"/>		
Demande de brevet initiale ou demande de certificat d'utilité initiale	N°	Date	/ /
	N°	Date	/ /
Transformation d'une demande de brevet européen Demande de brevet initiale	N°	Date	/ /

3 TITRE DE L'INVENTION (200 caractères ou espaces maximum)

L'hétérocarpine, une protéine fixant le GHRH humain

4 DÉCLARATION DE PRIORITÉ OU REQUÊTE DU BÉNÉFICE DE LA DATE DE DÉPÔT D'UNE DEMANDE ANTÉRIEURE FRANÇAISE		Pays ou organisation Date / / / N°
		Pays ou organisation Date / / / N°
		Pays ou organisation Date / / / N°
		<input type="checkbox"/> S'il y a d'autres priorités, cochez la case et utilisez l'imprimé «Suite»
5 DEMANDEUR		<input type="checkbox"/> S'il y a d'autres demandeurs, cochez la case et utilisez l'imprimé «Suite»
Nom ou dénomination sociale		SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.)
Prénoms		
Forme juridique		Société par Actions Simplifiée
N° SIREN		3 . 0 . 8 . 1 . 9 . 7 . 1 . 8 . 5
Code APE-NAF		17 . 4 . 1 . J
Adresse	Rue	51/53 rue du Docteur Blanche
	Code postal et ville	75016 PARIS
Pays		FRANCE
Nationalité		Française
N° de téléphone (facultatif)		(33) 01 44 30 42 00
N° de télécopie (facultatif)		(33) 01 42 88 86 91
Adresse électronique (facultatif)		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF TRANSLATION

Honourable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

I, JOHN CHARLES McGILLEY, B.A. M.I.T.I., Technical Translator, of c/o Priory Translations Limited, 11, Magdalen Street, Colchester, Essex, England, hereby state:


THAT I am well acquainted with the French and English languages.

THAT I translated the document identified as French Patent Application No. 01 02631 filed at the National Institute of Industrial Property on 27th February 2001, from French into English;

THAT the attached English translation is a true and correct translation of French Patent Application No. 01 02631.

to the best of my knowledge and belief; and

THAT all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true and further, that these statements are made with the knowledge that wilful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code


JOHN CHARLES McGILLEY

FRENCH REPUBLIC

inpi

NATIONAL INSTITUTE
OF INDUSTRIAL PROPERTY

Patent
of invention

Utility certificate

OFFICIAL COPY

The Director General of the National Institute of Industrial Property certifies that the document annexed hereto is the certified true copy of an application for title of industrial property registered at the Institute.

Drawn up in Paris, 7th June 2007

For the Director General
of the National Institute
of Industrial Property
The Head of the
Patent Department

Martine PLANCHE

INPI

PATENT OF INVENTION

National Institute of Industrial Property

26 bis, rue de Saint Petersbourg
75800 Paris Cedex 08
Tel: 01 53 04 53 04 Fax: 01 42 94 86 54

Utility certificate
Intellectual property code – Book VI
Request for grant 1/2

This form must be completed clearly in black ink

For INPI use only

Delivery of documents Date 27th February 2001 Place 75 INPI Paris National Registration No. assigned by INPI 0102631 Date of filing assigned by INPI 27th February 2001		1. Name and address of applicant or representative to whom correspondence should be addressed Monsieur André BOURGOIN BEAUFOUR IPSEN - S.C.R.A.S. Direction de la Propriété Industrielle 42 rue du Docteur Blanche 75016 PARIS
Your references for this file (optional) RS Cas 312 - AB/CG		
Confirmation of a filing by fax <input type="checkbox"/> no. assigned by INPI to the fax		
2. NATURE OF APPLICATION		Tick one of the following 4 boxes
Patent application		<input checked="" type="checkbox"/>
Application for utility certificate		<input type="checkbox"/>
Divisional application <i>Initial patent application or initial application for utility certificate</i>		<input type="checkbox"/> No. Date / / No. Date / /
Conversion of a European patent application <i>Initial patent application</i>		<input type="checkbox"/> No. Date / /
3. TITLE OF INVENTION (200 characters or spaces maximum) Heterocarpine, a human GHRH-binding protein		
4. DECLARATION OF PRIORITY OR REQUEST FOR BENEFIT FROM THE FILING DATE OF A PREVIOUS FRENCH APPLICATION		Country or organisation Date: / / No. Country or organisation Date: / / No. Country or organisation Date: / / No. <input type="checkbox"/> If there are other priorities, tick the box and use the printed form "Continuation"
5. APPLICANT		<input type="checkbox"/> If there are other applicants, tick the box and use the printed form "Continuation"
Name or title of company		SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.)
First names		
Legal form		Simplified joint stock company
SIREN no.		308197185
APE-NAF code		741J
Address	Street	51/53 rue du Docteur Blanche
	Post code and town	75016 PARIS
Country		FRANCE
Nationality		French
Telephone no. (optional)		(33) 01 44 30 42 00
Fax no. (optional)		(33) 01 42 88 86 91
Email address (optional)		

INPI

**National Institute
of Industrial Property**

PATENT OF INVENTION

**Utility certificate
Request for grant 2/2**

For INPI use only

Presentation of documents	
Date 27th February 2001	
Place 75 INPI Paris	
National Registration no. assigned by INPI 0102631	
Your references for this file: <i>(optional)</i>	
6. REPRESENTATIVE	
Name BOURGOUIN	
First name André	
Office or company BEAUFOUR IPSEN - S.C.R.A.S. Direction de la Propriété Industrielle	
No. of permanent power of attorney and/or contractual relationship	
In process of registration	
Address	Street 42 rue du Docteur Blanche
	Post code and town 75016 PARIS
Telephone no. <i>(optional)</i> (33) 01 44 55 96 10 10	
Fax no. <i>(optional)</i> (33) 01 44 55 96 13 42	
Email address <i>(optional)</i> andre.bourguoin@beaufour-ipsen.com	
7. INVENTOR(S)	
The inventors are the applicants	
<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No In this case, supply a separate designation of inventor(s)	
8. SEARCH REPORT	
Only for a patent application (including division and conversion)	
<input checked="" type="checkbox"/> <input type="checkbox"/>	
Immediate establishment or deferred establishment	
<input type="checkbox"/> Payment in two instalments, only for natural persons <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
9. REDUCTION IN LEVEL OF FEES	
Only for natural persons <input type="checkbox"/> Requested for the first time for this invention (<i>attach a notice of no charge</i>) <input type="checkbox"/> Requested prior to this filing (<i>attach a copy of the decision of acceptance for this invention or indicate its reference no.</i>)	
If you have used the printed form "Continuation", indicate the number of pages attached	
10. SIGNATURE OF APPLICANT OR REPRESENTATIVE: (name and capacity of signatory) André BOURGOUIN, Representative	
Stamp of prefecture or INPI C. TRAN	

The law no.78-17 of 6th January 1978 relating to data processing, files and freedoms applies to the replies given on this form. It guarantees the right of access and rectification for the data held about you with the INPI.

Heterocarpine, a human GHRH-binding protein

The present invention relates to a human GHRH-binding (human Growth Hormone releasing hormone) protein.

- Growth hormone ("GH") is a protein with 191 amino acids which stimulates the production of a number of growth factors, such as *Insulin-Like Growth Factor I* (IGF-1) and triggers the growth of a large number of tissues (skeleton, connective tissues, muscles and viscera). GH also has physiological activities, increasing the synthesis of the nucleic acids, proteins and lipolysis whilst reducing urinary secretions (Frohman L.A. & Kineman, R.D., *Handbook of Physiology*, Hormonal Control of Growth, edited by Kostyo, J.L. & Goodman, H.M. (Oxford Univ. Press, New York, 1999), p. 189-221).
- 5 The synthesis of GH is regulated by factors with positive or negative action secreted by the hypothalamus. The main factor controlling the production of GH is the "Growth Hormone Releasing Hormone" (GHRH), a peptide with 44 amino acids in humans.
- 10 GH and GHRH are involved in a number of diseases. Among these, the following should be mentioned in particular: cancer (in particular prostate or lung cancer), acromegaly, diabetic retinopathies and nephropathies; for these pathologies, treatment with GHRH antagonists is indicated. Due to the number of diseases potentially concerned, the industry continues to research GHRH antagonists.

- 15 The Applicant has therefore just isolated a new protein of vegetable origin, which has the property of binding human GHRH.
- 20 A first subject of the invention is therefore an isolated protein which can be obtained by extraction from the plant *Pilocarpus heterophyllus*, which is characterized in that it has a molecular mass of approximately 90.9 kDa and comprises fragments of peptide sequences SEQ.ID.NO.1, SEQ.ID.NO.2 and SEQ.ID.NO.3, said protein being able to be presented in a glycosylated or non-glycosylated form. In order to simplify the disclosure which follows, this protein is hereafter called "heterocarpine".
- 25

Said SEQ.ID.NO.1, SEQ.ID.NO.2 and SEQ.ID.NO.3 sequences are as follows:

SEQ.ID.NO.1:	KLIGARYFDK
SEQ.ID.NO.2:	YGEDIIVGVIDSGV
SEQ.ID.NO.3:	PESESY

- 5 The nomenclature used above (as in the remainder of the present Application) in order to define the peptides is that specified by the "IUPAC-IUB Commission on Biochemical Nomenclature" in which, in accordance with the standard representation, the N-terminal amino acid (amino group) appears on the left and the C-terminal amino acid (carboxyl group) appears on the right. The term "natural amino acid" indicates one of the natural
- 10 L-amino acids found in the natural proteins: Gly, Ala, Val, Leu, Ile, Ser, Thr, Lys, Arg, Asp, Asn, Glu, Gln, Cys, Met, Phe, Tyr, Pro, Trp and His.

A protein is called "isolated" if it is taken out of its original environment. In particular, a natural protein is isolated if it is separated from the biological material with which it coexists in the natural system.

- 15 The invention preferably relates to heterocarpine in its non-glycosylated form.

According to a preferred variant of the invention, the heterocarpine is obtained from an extract of cells of the plant *Pilocarpus Heterophyllus* cultured *in vitro*.

Moreover, a subject of the invention is also a monoclonal antibody, or an antigen binding fragment of the latter, which specifically binds heterocarpine.

- 20 Heterocarpine has the property of binding human GHRH. *In vitro*, heterocarpine binds human GHRH and thus inhibits the synthesis of cyclic AMP induced during the binding of human GHRH on its receptor. *In vivo*, in rats, the heterocarpine/human GHRH complex is formed in the blood compartment and, in dose-dependent manner inhibits the GH synthesis induced by 10 µg of human GHRH in a mole to mole ratio. The heterocarpine has the property of binding the human GHRH.
- 25

- 30 These properties render the compounds of the invention suitable for a pharmaceutical use. Therefore, a subject of the invention is also, as a medicament, heterocarpine in glycosylated or non-glycosylated form. It also relates to pharmaceutical compositions containing, as active ingredient, heterocarpine in a glycosylated or non-glycosylated form, said composition also comprising one or more pharmaceutically acceptable excipients. A further subject is the use of heterocarpine in a glycosylated or non-glycosylated form for preparing medicaments intended to antagonize the effects of

GHRH, to treat proliferative diseases (and in particular cancer), to treat acromegaly or to treat diabetic retinopathies and nephropathies. With regard to cancer, heterocarpine is particularly suitable for preparing a medicament intended to treat carcinoid and pancreatic tumors, hypothalamo-hypophyseal gangliocytomas, bronchial, intestinal and hepatic carcinomas, sympathoadrenergic tumors, pheochromocytomas, hypophyseal adenomas and thyroid carcinomas.

A subject of the invention is also, as a medicament, a monoclonal antibody, or an antigen binding fragment of the latter, which specifically binds heterocarpine. It also relates to a pharmaceutical composition comprising, as active ingredient, a monoclonal antibody, or an antigen binding fragment of the latter, which specifically binds heterocarpine, said composition also comprising one or more pharmaceutically acceptable excipients. It relates moreover to the use of a monoclonal antibody, or of an antigen binding fragment of the latter, which specifically binds heterocarpine, for preparing medicaments intended to antagonize the effects of GHRH, to treat proliferative diseases (and in particular cancer), to treat acromegaly or to treat diabetic retinopathies and nephropathies. As regards cancer, said monoclonal antibody or said antigen binding fragment of the latter is particularly suitable for preparing a medicament intended to treat carcinoid and pancreatic tumors, hypothalamo-hypophyseal gangliocytomas, bronchial, intestinal and hepatic carcinomas, sympathoadrenergic tumors, pheochromocytomas, hypophyseal adenomas and thyroid carcinomas.

Finally the invention relates to the use of heterocarpine as an excipient in a pharmaceutical composition intended for the sustained release of GHRH. It also relates to a pharmaceutical composition comprising GHRH, heterocarpine and one or more pharmaceutically acceptable excipients.

The pharmaceutical compositions containing a compound of the invention can be in solid form such as, for example, powders, pills, granules; tablets, liposomes, gelatin capsules or suppositories. The pills, tablets or gelatin capsules can be coated with a substance capable of protecting the composition from the action of gastric acid or the enzymes in the subject's stomach for a sufficient period of time to allow this composition to pass undigested into the latter's small intestine. The compound can also be administered locally, for example to the actual site of a tumor. The compound can also be administered according to a sustained-release process (for example by using a sustained-release composition or a perfusion pump). Appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, magnesium carbonate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine and wax.

The pharmaceutical compositions containing a compound of the invention can also be presented in liquid form such as, for example, solutions, emulsions, suspensions or a sustained-release formulation. Appropriate liquid supports can be, for example, water, organic solvents such as glycerol or glycols such as polyethylene glycol, as well as their mixtures, in varying proportions, in water.

5 The administration of a medicament according to the invention can be carried out by topical, oral, parenteral route, by intramuscular injection etc.

10 The dose of a compound according to the present invention, to be provided for the treatment of the above-mentioned diseases or disorders, varies depending on the administration method, the age and body weight of the subject to be treated as well as the state of the latter, and will be finally decided by the attending doctor or vet. Such a quantity determined by the attending doctor or vet is here called "therapeutically effective quantity".

15 In accordance with the invention, the heterocarpine can be prepared by the process described hereafter.

Preparation of heterocarpine

According to a preferred variant of the invention, *in vitro* cultures of calluses or of cell suspensions originating from different organs of the plant have been carried out. These tissues cultured on semi-solid or liquid medium are able to bio-synthesize compounds
20 having biological properties.

By "callus" is meant in the present Application a macroscopic cluster of undifferentiated cells of plants in culture on a semi-solid nutritive medium. The term "undifferentiated cells" in the present Application designates cells which have an aptitude under certain conditions to multiply in the form of a callus or of a cell suspension without any morphogenesis phenomenon. Finally, by "cell suspension", is meant undifferentiated cells which can form microscopic clusters in culture in a liquid nutrition medium.

25 The choice of the nutritive medium, hormones, culture conditions forms an integral part of the invention as well as the extraction and analysis of the extracts from these *in vitro* cultures.

Cells from *Pilocarpus Heterophyllus* seeds can be cultured in suspension for example according to the procedure hereafter.

The organs are decontaminated according to the usual methods before being cultured. Plantule organs *in vitro* have also served as callogenesis starting material without requiring disinfection beforehand. The preferred basic nutritive medium is one of the media commonly used for *in vitro* culture: this is Gamborg's medium (described in Gamborg et al., Nutrient requirements of suspension cultures of Soybean root cells, *Exp. Cell Res.* (1968), 50(1), 151-158). The carbon source is saccharose but glucose can also be used at a concentration of 1 to 120 g/l, preferably approximately 30 g/l. The macro-elements content can also be reduced by a factor of 2. Auxin or an auxin and a cytokinin are added to the medium, with a preference for a combination of both hormones, generally 2,4-dichlorophenoxyacetic acid and kinetin, but α-naphthaleneacetic acid (NAA), β-indoleacetic acid (IAA), β-indolbutanoic acid (IBA) or picloram can also be combined with the kinetin or benzylaminopurine (BAP). The concentration can vary from 0.1 to 10 mg/l for the auxin (for example 1 mg/l can be chosen), and from 0.01 to 2 mg/l for the cytokinin (for example 0.06 mg/l can be chosen). The vitamins are those associated with the different basic media. The cultures are carried out in light or in darkness. The temperature can vary from 10°C to 33°C but is preferentially 23°C. The pH of the medium is comprised between 4 and 6.5 and is preferentially adjusted to 5.8 before sterilization. Moreover, agar may or may not be added to the medium.

The primary calluses appear after a few days of culture and can be separated from the original implant, removed and subcultured after approximately 1 month then cultured on agar semi-solid medium (in tubes or Petri dishes), at intervals of 4 to 8 weeks, preferably 6 weeks, thus a callus can be kept for years by successive subcultures on new media. The callus can also be subcultured in a stirred liquid culture medium (Erlenmeyer flask or bioreactor) with subcultures at 2 to 6 weeks, preferably 3 weeks.

The strains obtained are distinguished by their genetic origin, culture conditions, appearance and absence of morphogenesis.

The lyophilized *Pilocarpus Heterophyllus* cells are extracted with water at a temperature of 0 to 50°C, and preferably 4 to 10°C. The extract thus obtained is lyophilized before being redissolved at a suitable concentration (for example approximately 30 % of dried matter). The proteins precipitated by the addition of a concentrated solution of ammonium sulphate (for example at a concentration representing 70 to 90 % of the saturation concentration) are dissolved in a minimum of water and the insoluble materials are recovered by centrifugation. The proteins are then

separated by column chromatography (the eluent preferably being water) and the heterocarpine (identifiable by its molecular mass of approximately 90.9 kDa) can then be recovered.

Preparation of antibodies specifically binding heterocarpine

- 5 The present invention provides binding agents, such as the antibodies which specifically bind heterocarpine. Such an agent is referred to as "specifically binding" a protein if it reacts at a detectable level (for example by an ELISA test) with said protein and does not detectably react with other proteins. "The binding" refers to a non-covalent association between 2 separate molecules such that a complex is formed. The binding
10 ability can be evaluated, for example, by determination of the binding constant for the formation of the complex. The binding constant is the value obtained when the value of the complex concentration is divided by the product of the values of the non-complexed component concentration. 2 products are called "bound" when the binding constant reaches 10³ l/mol. The binding constant can be determined using methods well known
15 to a person skilled in the art.

Any agent which can satisfy the above criteria can be regarded as a binding agent.

- In the present invention, a binding agent is preferably an antibody or a fragment of the latter. The antibodies can be prepared by any technique available to a person skilled in the art (cf. Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor
20 Laboratory, 1988). In general, the antibodies can be produced by cell culture techniques including the generation of monoclonal antibodies or via transfections of antibody genes into host cells from bacteria or mammals in order to produce recombinant antibodies.

- Among other techniques, use of those described hereafter is preferred. An immunogen containing heterocarpine is injected into a group of mammals (for example mice, rats,
25 rabbits, sheep or goats). In this stage, the heterocarpine can serve as immunogen without modification. Alternatively, a superior immune response can be induced if the heterocarpine is combined with a transport protein such as bovine serum albumin or limpet haemocyanin. The immunogen is injected into the host animal, preferably according to a predetermined schedule, and the animals are bled periodically. Polyclonal
30 antibodies specific to heterocarpine can thus be purified from such antiserum, for example, by affinity chromatography using heterocarpine coupled with an appropriate solid support.

Pharmaceutical compositions intended for the release of GHRH:

These compositions can in particular be prepared from heterocarpine and GHRH according to one of the methods described in the journal by De Wolf and Brett, *Pharmacological Reviews* (2000), **52**, 207-236 and the references cited therein.

- 5 Unless otherwise specified, all the technical and scientific terms used here have the same meaning as that usually understood by an ordinary specialist in the field to which this invention belongs. Similarly, all the publications, patent applications, all the patents and all other references mentioned here are incorporated by way of reference.

- 10 The following examples are presented in order to illustrate the above procedures and should in no event be considered as a limit to the scope of the invention.

Example : obtaining and characterization of heterocarpine

Culture of cells in vitro:

- A *Pilocarpus Heterophyllus* seed is germinated and the stem resulting from this germination is removed. Said stem is cultured in a Gamborg medium (Gamborg et al.,
 15 Nutrient requirements of suspension cultures of Soybean root cells, *Exp. Cell Res.* (1968), **50**(1), 151-158) to which 30 g/l of saccharose, 1 mg/l of 2,4-dichlorophenoxyacetic acid and 0.06 mg/l of kinetin have been added. The culture is carried out in tubes at a temperature of 23°C and in darkness. Subcultures are carried out every 6 weeks under usual conditions. The strains, which are granular in
 20 appearance, have a beige pigmentation.

- A growth kinetic of the strains, based on the increase in mass of fresh and dried material from the biomass, was carried out over 8 weeks. The calluses from 2 tubes are combined and constitute a twice-weekly harvest, the first harvest taking place at time 0. Calluses and gelose are then harvested and lyophilized. It is observed that growth is exponential up to 6 weeks of culture before the appearance of a stationary growth phase.
 25

Extraction of the cell cultures:

- 25 g of lyophilized *Pilocarpus Heterophyllus* cells are extracted twice by immersion in 375 ml of water at 4°C, and left overnight at 4°C, then in 250 ml of water at 4°C for 4
 30 hours and finally washed with 125 ml of water at 4°C. Each aqueous solution thus obtained is filtered under vacuum through a glass filter surmounted with celite in order to separate the cell debris from the aqueous solution. The aqueous solutions thus combined are then lyophilized in order to obtain 9.4 g of dried material. The lyophilized

dry extract is then dissolved in 31 ml of water at 20°C in order to obtain a solution containing 30 % of dry extract. 17.4 g of ammonium sulphate is added in small portions with constant magnetic stirring in order to precipitate the protein fraction. The protein precipitate is then separated from the ammonium sulphate solution by centrifugation at 5 3000 rpm for 20 minutes. The ammonium sulphate solution is decanted and the precipitated proteins are dissolved in 22 ml of water, re-centrifuged and filtered in order to eliminate the insoluble particles.

The filtrate obtained is then subjected to gel-filtration chromatography. It is injected into a column (Buchi N° 19678, L = 230 mm; internal diameter = 26 mm) filled with 10 Superdex™ 200 (Amersham Pharmacia Biotech, reference no. 17-1043-01; particles with an average diameter of 13 µm) prepared according to the manufacturer's recommendations using ultra-pure water (Water's Milli-Q) as eluent at a flow rate of 5 ml per minute. 40 ml fractions are thus collected and the active protein is found in the third and fourth fraction. These fractions are lyophilized in order to obtain 15 approximately 14.2 mg of active product.

The purity of the product obtained is demonstrated by the appearance of a single band on electrophoresis gel containing sodium dodecylsulphate (SDS PAGE). The product corresponding to this band is designated hereafter as heterocarpine.

Analysis and micro-sequencing:

20 The samples are loaded onto a 10 % polyacrylamide gel. After migration, the gels are fixed and stained with Coomassie blue.

The gel tracks represented in **Figure 3** corresponding to tracks 1, 2, 3, 4 and 5 are respectively the molecular weight marker (Amersham), 0.5, 1 and 2 µg of the content of the final heterocarpine fraction and the molecular mass marker (Amersham). 25 Determination of the molecular mass by means of a standard molecular mass marker graph using standard computing tools well known to a person skilled in the art (for example, Viber Lourmat's Bio-Profil Bio1D software) makes it possible to show that heterocarpine has a molecular mass of 90.9 kiloDaltons (\pm 1.6 kiloDaltons).

30 For protein micro-sequencing analysis, the band of polyacrylamide containing the protein is cut out and digested in 300 µl of digestion buffer containing 50 mM Tris (pH 8.6), 0.03 % of sodium dodecylsulphate at 35°C for 18 hours in the presence of 0.4 µg of endolysine-C (Sigma). The peptides obtained are separated, by HPLC, on a DEAE-C18 in-line column 1 mm in diameter. The separation gradient is based on a mixture of acetonitrile (from 2 to 70 %) and 0.1 % trifluoroacetic acid (TFA). The sequencing is 35 then carried out on a Procise sequencer (Applied Biosystem). In this way three peaks have been sequenced, making it possible to characterize heterocarpine in a unique

manner. The corresponding sequences are identified in the present Application by SEQ.ID.NO.1, SEQ.ID.NO.2 and SEQ.ID.NO.3.

- Analysis of the glycoproteins is carried out by the detection of sugared structures of the glycoproteins separated by SDS-PAGE gel. This detection system is a modification of the "Periodic acid-Schiff" methods and leads to the appearance of magenta bands showing evidence of the glycoproteins (Sigma). The result reproduced in **Figure 4** is obtained.

Pharmacological properties of heterocarpine

Stable transfections of the human GHRH receptor (hGHRH-R):

- 10 Human embryo kidney cells, HEK-293, (a cell line developed by Dr. Stuart Sealfon, Mount Sinai Medical School, New York, New York) expressing the human GHRH receptor in stable manner were obtained from Dr. Kelly Mayo (Northwestern University, Chicago, IL).

Cell culture and membrane preparation:

- 15 The HEK-293 cells transfected in a stable manner with the human GHRH receptor described above are cultured in DMEM (Dulbecco's modified Eagle's medium, high glucose content; supplied by Life technologies) supplemented with 0.4 mg/ml of G418 (Life technologies) in the presence of 10 % of foetal calf serum and 4 mM of L-glutamine (Life technologies). The cells are homogenized in buffer A containing 50 mM HEPES (pH 7.4), 5 mM of magnesium chloride ($MgCl_2$), 2 mM of ethyleneglycol-bis(2-amino-ethyl)-N,N,N',N'-tetraacetic acid (EGTA) and 50 μ g/ml of bacitracin then are subjected to sonication in the same buffer A. The cells thus homogenized are centrifuged at 4°C at 39,000 g for 10 minutes, suspended in buffer A and re-centrifuged at 4°C at 40,000 g for 10 minutes. The total membrane proteins are quantified by Bradford's technique. The pelleted membranes are thus stored at -80°C for later use.

Competitive binding test on hGHRH-R:

- The membranes of the HEK-293 cells transfected in a stable manner with the human GHRH receptor are diluted to a concentration of 100 μ g/ml in the reaction buffer containing 50 mM HEPES (pH 7.4), 5 mM of $MgCl_2$, 2 mM of EGTA, 50 μ g/ml of bacitracin and 0.5 % of bovine serum albumin (BSA). The membranes are incubated with 0.05 nM of [^{125}I]GHRH(1-44 amide) (Amersham) in a final volume of 200 μ l in the presence of increasing concentrations of heterocarpine for 2 hours at 23°C. The

reaction is stopped by rapid filtration on 96-well GF/C filters 0.1 % pre-loaded with polyethylenimine. The filters are then washed three times at 4°C with washing buffer containing 50 mM Tris (pH 7.4) using a Packard 96-well filtration station. The filters thus dried are submerged in 20 µl of scintillating cocktail (Microscint O, Packard) and 5 are subjected to Topcount counting (Packard). The non-specific activity is determined in the presence of 100 nM of hGHRH. A dose-response curve is generated for hGHRH (0.001 nM-100 nM) and the results obtained are included in **Figure 1**.

Competitive formation of cyclic AMP:

10 The HEK-293 cells transfected in a stable manner with the human GHRH receptor are distributed in 48-well culture plates and cultured for 3 days. The culture medium is then removed and replaced by medium B containing 250 µl of DMEM (Dulbecco's modified Eagle's medium, high glucose content; supplied by Life technologies) in the presence of 0.5 % of BSA, 0.5 mM of 3-isobutyl-1-methylxanthine (IBMX) and pre-incubated for 5 minutes at 37°C. At the end of the pre-incubation period, the heterocarpine is tested for 15 an additional 20 minutes. The concentrations observed are reported in **Figure 2**. The incubation is stopped by the addition of 100 µl of 0.1M HCl and the aliquots are analysed for their cyclic AMP content using the FlashPlate kit (New England Nuclear).

Assay of GH in rats:

20 Levels of GH in rats (Sprague Dawley males) are measured in blood samples by an enzymo-immunological test developed by Spi-Bio (Spi-Bio, France). The rats are treated by intravenous injection of heterocarpine at increasing doses (vehicle alone, 1, 3 and 10 nmol), then, 10 minutes after, by intravenous injection of 10 µg (3 nmol) of hGHRH. Ten minutes after injection of the hGHRH, the growth hormone levels are measured in the blood samples as described above. The results obtained are represented 25 in **Figure 5**.

Brief description of the figures:

Figure 1 is a graph representing the inhibition of binding of human GHRH on the human GHRH receptor as a function of increasing concentrations of heterocarpine.

30 **Figure 2** is a graph representing the inhibition of the production of cyclic AMP in cells transfected in a stable manner with the human GHRH receptor in the presence of 10 nM of human GHRH as a function of increasing concentrations of heterocarpine.

Figure 3 is a reproduction of an SDS-PAGE protein gel plate showing the presence of heterocarpine having a molecular weight of 90.9 kDa.

Figure 4 is a reproduction of an SDS-PAGE protein gel plate showing that heterocarpine is a glycoprotein (Panel B).

Figure 5 is a representation in histogram form representing the inhibition of GH synthesis in rats in the presence of 10 µg of human GHRH as a function of increasing concentrations of heterocarpine.

Claims

1. Isolated protein which can be obtained by extraction from the plant *Pilocarpus heterophyllus*, which is characterized in that it has a molecular mass of approximately 90.9 kDa and comprises fragments of peptide sequences SEQ.ID.NO.1, SEQ.ID.NO.2 and SEQ.ID.NO.3; said protein be able to be presented in a glycosylated or non-glycosylated form.
- 5 2. Protein according to claim 1, characterized in that it has been obtained from an extract from cells of the plant *Pilocarpus Heterophyllus* cultured *in vitro*.
3. As a medicament, a protein according to claim 1 or 2.
- 10 4. Monoclonal antibody, or an antigen binding fragment of the latter, which specifically binds the isolated protein of claim 1.
5. As a medicament, a monoclonal antibody, or an antigen binding fragment of the latter, which specifically binds the isolated protein of claim 1.
- 15 6. Pharmaceutical composition comprising, as active ingredient, a protein according to claim 1 or 2, as well as one or more pharmaceutically acceptable excipients.
7. Use of a protein according to claim 1 or 2 for preparing a medicament intended to antagonize the effects of GHRH.
8. Use of a protein according to claim 1 or 2 for preparing a medicament intended to treat a proliferative disease, in particular cancer.
- 20 9. Use of a protein according to claim 1 or 2 for preparing a medicament intended to treat acromegaly.
10. Use of a protein according to claim 1 or 2 for preparing a medicament intended to treat diabetic retinopathies and nephropathies.




Figure 1




Figure 2




Figure 3





Figure 4




Figure 5

SEQUENCE LISTING

<110> SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION
<120> Heterocarpine, a human GHRH-binding protein
<130> Heterocarpine
<140>
<141>
<160> 3

<170> PatentIn Ver. 2.1

<210> 1
<211> 10
<212> PRT
<213> **Pilocarpus Heterophyllus**

<400> 1
Lys Leu Ile Gly Ala Arg Tyr Phe Asp Lys
1 5 10

<210> 2
<211> 14
<212> PRT
<213> **Pilocarpus Heterophyllus**

<400> 2
Tyr Gly Glu Asp Ile Ile Val Gly Val Ile Asp Ser Gly Val
1 5 10

<210> 3
<211> 6
<212> PRT
<213> **Pilocarpus Heterophyllus**

<400> 3
Pro Glu Ser Glu Ser Tyr
1 5

INPI
National Institute of
Industrial Property

PATENT OF INVENTION
Utility certificate
Intellectual property code – Book VI

cerfa

No. 11235'02

Patent Department
26 bis, rue de Saint Petersbourg
7500 Paris Cedex 08
Tel: 01 53 04 53 04 Fax: 01 42 93 59 30

Designation of inventor(s) Page no. 1/2
(If the applicant is not the inventor or
the sole inventor)

This form must be completed clearly in black ink

Your references for this file (optional)		RS Cas 312 AB/CG
National registration no. 0102631		
Title of the invention (200 characters or spaces maximum) Heterocarpine, a human GHRH-binding protein		
Applicant(s): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 51/53 rue du Docteur Blanche 75016 PARIS FRANCE		
Designate(s) as inventor(s): (Indicate top right "Page no. 1/1". If there are more than three inventors, use an identical form and number each page, indicating the total number of pages).		
Name		FERRANDIS
First names		Eric
Address	Street	74 avenue Guy de Coubertin
	Post code and town	78470 SAINT REMY LES CHEVREUSE
Member company (optional)		
Name		TENG
First names		Beng Poon
Address	Street	6 chemin de la grange
	Post code and town	91190 GIF-SUR-YVETTE
Member company (optional)		
Name		SOHIER
First names		Christine
Address	Street	30 rue des Aubuis - Les Fourneaux
	Post code and town	37390 SAINT ROCH
Member company (optional)		
DATE AND SIGNATURE(S) OF APPLICANT(S) OR REPRESENTATIVE (Name and capacity of signatory)		

The law no. 78-17 of 6th January 1978 relating to data processing, files and freedoms applies to the replies given on this form. It guarantees the right of access and rectification for the data held about you with the INPI.

INPI
National Institute of
Industrial Property

Patent Department
26 bis, rue de Saint Petersbourg
7500 Paris Cedex 08
Tel: 01 53 04 53 04 Fax: 01 42 94 86 54

PATENT OF INVENTION**Utility certificate***cerfa*

No. 11235/02

Intellectual property code – Book VI

Designation of inventor(s) Page no. 2/2
 (If the applicant is not the inventor or
 the sole inventor)

This form must be completed clearly in black ink

Your references for this file (optional)	RS 312 AB/CG
National registration no.	0102631
Title of the invention (200 characters or spaces maximum) Heterocarpine, a human GHRH-binding protein	
Applicant(s): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 51/53 rue du Docteur Blanche 75016 PARIS FRANCE	
Designate(s) as inventor(s): (Indicate top right "Page no. 1/1". If there are more than three inventors, use an identical form and number each page, indicating the total number of pages).	
Name	THURIEAU
First names	Christophe
Address	Street 84 avenue Kléber Post code and town 75016 PARIS
Member company (optional)	
Name	
First names	
Address	Street Post code and town
Member company (optional)	
Name	
First names	
Address	Street Post code and town
Member company (optional)	
DATE AND SIGNATURE(S) OF APPLICANT(S) OR REPRESENTATIVE (Name and capacity of signatory) Paris, 22th February 2001	
André BOURGOUIN, Representative	

The law no. 78-17 of 6th January 1978 relating to data processing, files and freedoms applies to the replies given on this form. It guarantees the right of access and rectification for the data held about you with the INPI.